Mohamed S Elfarargy1, Ghada M Al-Ashmawy2, Sally M Abu-Risha3, Haidy A Khattab4. 1. Department of Pediatrics (MSE), Faculty of Medicine, Tanta University, City, Country. 2. Department of Biochemistry (GMA-A), Faculty of Pharmacy, Tanta University, City, Country. 3. Department of Pharmacology (SMA-R), Faculty of Pharmacy, Tanta University, City, Country. 4. Department of Physiology (HAK), Faculty of Medicine, Tanta University, Tanta, Egypt.
Abstract
OBJECTIVE: This study evaluates the value of inhaled budesonide (BUD) administration in neonatal respiratory distress syndrome (RDS) cases especially for near-term neonates. METHODS: A randomized controlled trial involving 120 neonates with respiratory distress, which was diagnosed as RDS, was conducted from July 2016 to March 2018. The neonates studied were divided into 2 groups: group 1 (the inhaled BUD group), consisting of 60 neonates who received BUD (2 mL, 0.25-mg/mL suspension) inhalation, twice daily for 5 days; and group 2 (the placebo group), consisting of 60 neonates with RDS who received humidified distilled sterile water inhalation (2 mL). Downes score, RDS grades, and interleukin 8 (IL-8) levels were monitored and measured on the first and fifth days of incubation. RESULTS: Statistically significant differences (SSDs) in RDS grades, Downes score, and IL-8 levels on the fifth day of admission were observed between groups 1 and 2 (p = 0.001) and between the first and fifth days of incubation in group 1 (p = 0.001). The SSDs in the duration of hospitalization (p = 0.001) and the number of neonates receiving mechanical ventilation (p = 0.032) were found between both groups. CONCLUSIONS: Budesonide inhalation is associated with improvements in clinical and laboratory parameters in neonates with RDS. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
OBJECTIVE: This study evaluates the value of inhaled budesonide (BUD) administration in neonatal respiratory distress syndrome (RDS) cases especially for near-term neonates. METHODS: A randomized controlled trial involving 120 neonates with respiratory distress, which was diagnosed as RDS, was conducted from July 2016 to March 2018. The neonates studied were divided into 2 groups: group 1 (the inhaled BUD group), consisting of 60 neonates who received BUD (2 mL, 0.25-mg/mL suspension) inhalation, twice daily for 5 days; and group 2 (the placebo group), consisting of 60 neonates with RDS who received humidified distilled sterile water inhalation (2 mL). Downes score, RDS grades, and interleukin 8 (IL-8) levels were monitored and measured on the first and fifth days of incubation. RESULTS: Statistically significant differences (SSDs) in RDS grades, Downes score, and IL-8 levels on the fifth day of admission were observed between groups 1 and 2 (p = 0.001) and between the first and fifth days of incubation in group 1 (p = 0.001). The SSDs in the duration of hospitalization (p = 0.001) and the number of neonates receiving mechanical ventilation (p = 0.032) were found between both groups. CONCLUSIONS: Budesonide inhalation is associated with improvements in clinical and laboratory parameters in neonates with RDS. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
Authors: Dirk Bassler; Richard Plavka; Eric S Shinwell; Mikko Hallman; Pierre-Henri Jarreau; Virgilio Carnielli; Johannes N Van den Anker; Christoph Meisner; Corinna Engel; Matthias Schwab; Henry L Halliday; Christian F Poets Journal: N Engl J Med Date: 2015-10-15 Impact factor: 91.245
Authors: Nehal A Parikh; Robert G Locke; Aaron Chidekel; Kathleen H Leef; John Emberger; David A Paul; John L Stefano Journal: J Am Osteopath Assoc Date: 2004-03